These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 30477725)
1. Association of Plasma Lipoprotein(a) With Long-Term Adverse Events in Patients With Chronic Kidney Disease Who Underwent Percutaneous Coronary Intervention. Xu N; Tang XF; Yao Y; Zhao XY; Chen J; Gao Z; Qiao SB; Yang YJ; Gao RL; Xu B; Yuan JQ Am J Cardiol; 2018 Dec; 122(12):2043-2048. PubMed ID: 30477725 [TBL] [Abstract][Full Text] [Related]
2. Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Konishi H; Miyauchi K; Tsuboi S; Ogita M; Naito R; Dohi T; Kasai T; Tamura H; Okazaki S; Isoda K; Daida H Int J Cardiol; 2016 Feb; 205():50-53. PubMed ID: 26710333 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a) levels are associated with coronary severity but not with outcomes in Chinese patients underwent percutaneous coronary intervention. Xu N; Tang XF; Yao Y; Jia SD; Liu Y; Zhao XY; Chen J; Gao Z; Yang YJ; Gao RL; Xu B; Yuan JQ Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):265-273. PubMed ID: 31740238 [TBL] [Abstract][Full Text] [Related]
4. Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention. Konishi H; Miyauchi K; Shitara J; Endo H; Wada H; Doi S; Naito R; Tsuboi S; Ogita M; Dohi T; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H Am J Cardiol; 2016 Dec; 118(12):1781-1785. PubMed ID: 27712648 [TBL] [Abstract][Full Text] [Related]
5. Sex-based differences in bleeding and long-term adverse events after percutaneous coronary intervention in older patients with coronary artery disease. Xu N; Tang XF; Zhao XY; Chen J; Gao Z; Qiao SB; Yang YJ; Gao RL; Xu B; Yuan JQ J Interv Cardiol; 2018 Jun; 31(3):345-352. PubMed ID: 29490431 [TBL] [Abstract][Full Text] [Related]
6. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention. Suwa S; Ogita M; Miyauchi K; Sonoda T; Konishi H; Tsuboi S; Wada H; Naito R; Dohi T; Kasai T; Okazaki S; Isoda K; Daida H J Atheroscler Thromb; 2017 Nov; 24(11):1125-1131. PubMed ID: 28321012 [TBL] [Abstract][Full Text] [Related]
7. Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention. Konishi H; Miyauchi K; Kasai T; Tsuboi S; Ogita M; Naito R; Sai E; Fukushima Y; Katoh Y; Okai I; Tamura H; Okazaki S; Daida H Am J Cardiol; 2015 Jan; 115(2):157-60. PubMed ID: 25476560 [TBL] [Abstract][Full Text] [Related]
8. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents. Sai E; Shimada K; Miyauchi K; Masaki Y; Kojima T; Miyazaki T; Kurata T; Ogita M; Tsuboi S; Yoshihara T; Miyazaki T; Ohsaka A; Daida H Heart Vessels; 2016 May; 31(5):694-701. PubMed ID: 25863806 [TBL] [Abstract][Full Text] [Related]
9. Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention. Feng Z; Li HL; Bei WJ; Guo XS; Wang K; Yi SX; Luo DM; Li XD; Chen SQ; Ran P; Chen PY; Islam SMS; Chen JY; Liu Y; Zhou YL Clin Cardiol; 2017 Sep; 40(9):674-678. PubMed ID: 28444976 [TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention. Takahashi N; Dohi T; Funamizu T; Endo H; Wada H; Doi S; Kato Y; Ogita M; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Shimada K J Cardiol; 2020 Jul; 76(1):25-29. PubMed ID: 32089480 [TBL] [Abstract][Full Text] [Related]
12. Association between Lipoprotein(a) concentration and adverse cardiac events in patients with coronary artery disease: An observational cohort study. Amin N; Devasia T; Kamath SU; Paramasivam G; Shetty PN; Singh A; Prakash N S G Indian Heart J; 2024; 76(3):197-201. PubMed ID: 38871220 [TBL] [Abstract][Full Text] [Related]
13. Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Long-Term Follow-up Study on Real-World Patients Receiving Percutaneous Coronary Intervention. Liu HH; Cao YX; Jin JL; Zhang HW; Hua Q; Li YF; Guo YL; Zhu CG; Wu NQ; Xu RX; Chen XH; Li JJ J Am Heart Assoc; 2020 Feb; 9(3):e014581. PubMed ID: 32013705 [TBL] [Abstract][Full Text] [Related]
14. LDL-C and hs-CRP Jointly Modify the Effect of Lp(a) on 5-Year Death in Patients With Percutaneous Coronary Intervention. Li J; Yan K; Zhu P; Tang X; Yang Y; Gao R; Yuan J; Zhao X Clin Cardiol; 2024 Oct; 47(10):e70025. PubMed ID: 39428896 [TBL] [Abstract][Full Text] [Related]
15. Inverse Association of Lipoprotein(a) on Long-Term Bleeding Risk in Patients with Coronary Heart Disease: Insight from a Multicenter Cohort in Asia. Wang P; Yuan D; Zhao X; Zhu P; Guo X; Jiang L; Xu N; Wang Z; Liu R; Wang Q; Chen Y; Zhang Y; Xu J; Liu Z; Song Y; Zhang Z; Yao Y; Feng Y; Tang X; Wang X; Gao R; Han Y; Yuan J Thromb Haemost; 2024 Jul; 124(7):684-694. PubMed ID: 37487540 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention. Yuan D; Wang P; Jia S; Zhang C; Zhu P; Jiang L; Liu R; Xu J; Tang X; Song Y; Yao Y; Xu N; Zhang Y; Zhao X; Yang Y; Xu B; Gao L; Gao Z; Gao R; Yuan J Atherosclerosis; 2022 Dec; 363():109-116. PubMed ID: 36357218 [TBL] [Abstract][Full Text] [Related]
17. Impact of Chronic Kidney Disease on Cardiovascular and Renal Events in Patients Undergoing Percutaneous Coronary Intervention with Everolimus-Eluting Stent: Risk Stratification with C-Reactive Protein. Dan K; Miyoshi T; Nakahama M; Mizuno T; Kagawa K; Naito Y; Kawada S; Ito H Cardiorenal Med; 2018; 8(2):151-159. PubMed ID: 29617004 [TBL] [Abstract][Full Text] [Related]
18. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385 [TBL] [Abstract][Full Text] [Related]
19. The prognostic implications of chronic kidney disease and anemia on long-term outcomes in patients undergoing percutaneous coronary intervention. Takeuchi M; Dohi T; Takahashi N; Endo H; Doi S; Kato Y; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Minamino T Heart Vessels; 2021 Aug; 36(8):1117-1124. PubMed ID: 33606067 [TBL] [Abstract][Full Text] [Related]
20. Five-year mortality outcomes in patients with chronic kidney disease undergoing percutaneous coronary intervention. Patel AD; Ibrahim M; Swaminathan RV; Minhas IU; Kim LK; Venkatesh P; Feldman DN; Minutello RM; Bergman GW; Wong SC; Singh HS Catheter Cardiovasc Interv; 2017 Mar; 89(4):E124-E132. PubMed ID: 27519355 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]